T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 6, 2011, Pages 1387-1395

  Kuo, Sung Hsin ^a,b   Cheng, Ann Lii ^a,b,c   Lin, Chung Wu ^a   Hsu, Chih Hung ^a,b   Wu, Ming Shiang ^a   Yeh, Kun Huei ^a,b   Tzeng, Yi Shin ^a,b   Chen, Li Tzong ^c,d,e  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

API2 MALT1; MALT lymphoma; NF B; Stomach; Thalidomide

Indexed keywords

ANTIBIOTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PREDNISOLONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; API2 MALT1 FUSION GENE; ARTICLE; B CELL LYMPHOMA; BONE MARROW; BONE MARROW RELAPSE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER TISSUE; CD3+ T LYMPHOCYTE; CHROMOSOME 11Q; CHROMOSOME 18Q; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 18; CLINICAL ARTICLE; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; EOSINOPHIL COUNT; ERADICATION THERAPY; EVENT FREE SURVIVAL; FEMALE; FUSION GENE; GENE EXPRESSION; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LYMPHOCYTIC INFILTRATION; MALE; MICROVASCULAR DENSITY; MONOTHERAPY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NEUTROPHIL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALVAGE THERAPY; STOMACH LYMPHOMA; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

AGED; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 18; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NF-KAPPA B; ONCOGENE PROTEINS, FUSION; SALVAGE THERAPY; STOMACH NEOPLASMS; THALIDOMIDE; TRANSLOCATION, GENETIC;

EID: 82455212066     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1631-y     Document Type: Article

References (31)

1. PG Isaacson MQ Du 2005 Gastrointestinal lymphoma: where morphology meets molecular biology J Pathol 205 255 274 15643667 10.1002/path.1703 1:CAS:528:DC%2BD2MXhsFOgsrg%3D (Pubitemid 40227996)
2. E Zucca F Bertoni A Stathis F Cavalli 2008 Marginal zone lymphomas Hematol Oncol Clin North Am 22 883 901 18954742 10.1016/j.hoc.2008.07.011
3. MQ Du JC Atherton 2006 Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management Gut 55 886 893 16698756 10.1136/gut.2004.061663 1:CAS:528:DC%2BD28XlvVOhtL0%3D (Pubitemid 43764563)
4. Zucca E, Dreyling M (2008) Gastric marginal zone lymphoma of MALT type: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(Suppl 2):ii70-ii71
5. KI Mafune Y Tanaka Y Suda T Izumo 2001 Outcome of patients with non-Hodgkin's lymphoma of the stomach after gastrectomy: clinicopathological study and reclassification according to the REAL classification Gastric Cancer 4 137 143 11760079 10.1007/PL00011736 1:STN:280:DC%2BD38%2Fjt1WjsA%3D%3D (Pubitemid 33123476)
6. C Vrieling D de Jong H Boot JP de Boer F Wegman BM Aleman 2008 Long-term results of stomach-conserving therapy in gastric MALT lymphoma Radiother Oncol 87 405 411 18343513 10.1016/j.radonc.2008.02.012
7. H Liu H Ye A Ruskone-Fourmestraux D De Jong S Pileri C Thiede A Lavergne H Boot G Caletti T Wündisch T Molina BG Taal S Elena T Thomas PL Zinzani A Neubauer M Stolte RA Hamoudi A Dogan PG Isaacson MQ Du 2002 T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication Gastroenterology 122 1286 1294 11984515 10.1053/gast.2002.33047 1:CAS:528:DC%2BD38Xkt1CrurY%3D (Pubitemid 34465171)
8. Y Kaneko S Sakurai M Hironaka S Sato S Oguni Y Sakuma K Sato K Sugano K Saito 2003 Distinct methylated profiles in Helicobacter pylori dependent and independent gastric MALT lymphomas Gut 52 641 646 12692046 10.1136/gut.52.5.641 1:CAS:528:DC%2BD3sXjvVeiurc%3D (Pubitemid 36528863)
9. KH Yeh SH Kuo LT Chen TL Mao SL Doong MS Wu HC Hsu YS Tzeng CL Chen JT Lin AL Cheng 2005 Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21) Blood 106 1037 1041 15845895 10.1182/blood-2005-01-0004 1:CAS:528: DC%2BD2MXntVSmsrg%3D (Pubitemid 41076451)
10. PY Yeh SH Kuo KH Yeh SE Chuang CH Hsu WC Chang HI Lin M Gao AL Cheng 2006 A pathway for TNF-alpha-induced Bcl10 nuclear translocation: Bcl10 is upregulated by NF-kappa B, phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus J Biol Chem 281 167 175 16280327 10.1074/jbc.M511014200 1:CAS:528:DC%2BD28Xht1emtw%3D%3D (Pubitemid 43671175)
11. SH Kuo LT Chen MS Wu CW Lin KH Yeh KT Kuo PY Yeh YS Tzeng HP Wang PN Hsu JT Lin AL Cheng 2008 Long-term follow-up of gastrectomized patients with MALT lymphoma-need for a revisit of surgical treatment Ann Surg 247 265 269 18216531 10.1097/SLA.0b013e3181582364 (Pubitemid 351156768)
12. S Singhal J Mehta R Desikan D Ayers P Roberson P Eddlemon N Munshi E Anaissie C Wilson M Dhodapkar J Zeddis B Barlogie 1999 Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1565 1571 10564685 10.1056/NEJM199911183412102 1:CAS:528:DyaK1MXotVSgs78%3D
13. S Kumar TE Witzig SV Rajkumar 2004 Thalidomide: current role in the treatment of non-plasma cell malignancies J Clin Oncol 22 2477 2488 15197211 10.1200/JCO.2004.10.127 1:CAS:528:DC%2BD2cXpsVWksrw%3D (Pubitemid 41115407)
14. T Hideshima D Chauhan Y Shima N Raje FE Davies YT Tai SP Treon B Lin RL Schlossman P Richardson G Muller DI Stirling KC Anderson 2000 Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 96 2943 2950 11049970 1:CAS:528:DC%2BD3cXnslGnsbw%3D
15. K Neben J Mytilineos TM Moehler A Preiss A Kraemer AD Ho G Opelz H Goldschmidt 2002 Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma Blood 100 2263 2265 12200397 1:CAS:528:DC%2BD38Xnt1yhtrw%3D (Pubitemid 35001268)
16. JA Keifer DC Guttridge BP Ashburner AS Baldwin Jr 2001 Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity J Biol Chem 276 22382 22387 11297551 10.1074/jbc.M100938200 1:CAS:528:DC%2BD3MXkvVamsro%3D
17. A Delmonte M Ghielmini C Sessa 2009 Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas Oncologist 14 511 525 19411316 10.1634/theoncologist.2008-0214 1:CAS:528:DC%2BD1MXnvVOlsbY%3D
18. JK Chan CS Ng PG Isaacson 1990 Relationship between high-grade lymphoma and low-grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) of the stomach Am J Pathol 136 1153 1164 2349966 1:STN:280:DyaK3c3nsVSmtQ%3D%3D (Pubitemid 20188502)
19. H Ye A Dogan L Karran TG Willis L Chen I Wlodarska MJ Dyer PG Isaacson MQ Du 2000 BCL10 expression in normal and neoplastic lymphoid tissue: nuclear localization in MALT lymphoma Am J Pathol 157 1147 1154 11021819 10.1016/S0002-9440(10)64630-5 1:CAS:528:DC%2BD3cXnsVKjur0%3D
20. SH Kuo PY Yeh LT Chen MS Wu CW Lin KH Yeh YS Tzeng JY Chen PN Hsu JT Lin AL Cheng 2008 Overexpression of B-cell activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma Blood 112 2927 2934 18628489 10.1182/blood-2008-02-137513 1:CAS:528:DC%2BD1cXht1SrtbzJ
21. G Mazur T Wróbel P Dziegiel M Jeleń K Kuliczkowski M Zabel 2004 Angiogenesis measured by expression of CD34 antigen in lymph nodes of patients with non-Hodgkin's lymphoma Folia Histochem Cytobiol 42 241 243 15704651 (Pubitemid 39481032)
22. HA Alshenawy 2010 Prognostic significance of vascular endothelial growth factor, basic fibroblastic growth factor, and microvessel density and their relation to cell proliferation in B-cell non-Hodgkin's lymphoma Ann Diagn Pathol 14 321 327 20850693 10.1016/j.anndiagpath.2009.12.011
23. SH Kuo LT Chen KH Yeh MS Wu HC Hsu PY Yeh TL Mao CL Chen SL Doong JT Lin AL Cheng 2004 Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas J Clin Oncol 22 3491 3497 15337797 10.1200/JCO.2004.10.087 1:CAS:528:DC%2BD2cXpsVWkurk%3D (Pubitemid 41103655)
24. BD Cheson B Pfistner ME Juweid RD Gascoyne L Specht SJ Horning B Coiffier RI Fisher A Hagenbeek E Zucca ST Rosen S Stroobants TA Lister RT Hoppe M Dreyling K Tobinai JM Vose JM Connors M Federico V Diehl 2007 International harmonization project on lymphoma. Revised response criteria for malignant lymphoma J Clin Oncol 25 579 586 17242396 10.1200/JCO.2006.09.2403 (Pubitemid 350002966)
25. SM Smith D Grinblatt JL Johnson D Niedzwiecki D Rizzieri NL Bartlett BD Cheson Cancer and Leukemia Group B 2008 Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B Br J Haematol 140 313 319 18217897 10.1111/j.1365-2141.2007.06937.x 1:CAS:528:DC%2BD1cXitlakt7s%3D (Pubitemid 351209487)
26. B Pro A Younes M Albitar NH Dang F Samaniego J Romaguera P McLaughlin FB Hagemeister MA Rodriguez M Clemons F Cabanillas 2004 Thalidomide for patients with recurrent lymphoma Cancer 100 1186 1189 15022285 10.1002/cncr.20070 1:CAS:528:DC%2BD2cXivFagsbY%3D (Pubitemid 38325946)
27. M Kees M Raderer S Metz-Schimmerl A Chott H Gisslinger 2005 Very good partial response in a patient with MALT-lymphoma of the lung after treatment with low-dose thalidomide Leuk Lymphoma 46 1379 1382 16109619 10.1080/10428190500144649 1:CAS:528:DC%2BD2MXpslyktLg%3D (Pubitemid 41269308)
28. M Troch C Zielinski M Raderer 2009 Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) Ann Oncol 20 1446 1447 19654203 10.1093/annonc/mdp349 1:STN:280:DC%2BD1MrjsFSktw%3D%3D
29. H Zhou MQ Du VM Dixit 2005 Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity Cancer Cell 7 425 431 15894263 10.1016/j.ccr.2005.04.012 1:CAS:528:DC%2BD2MXkslyit7Y%3D (Pubitemid 40719126)
30. Y Hosokawa H Suzuki M Nakagawa TH Lee M Seto 2005 API2-MALT1 fusion protein induces transcriptional activation of the API2 gene through NF-kappaB binding elements: evidence for a positive feed-back loop pathway resulting in unremitting NF-kappaB activation Biochem Biophys Res Commun 334 51 60 15982633 10.1016/j.bbrc.2005.06.058 1:CAS:528:DC%2BD2MXmt1aqsLg%3D (Pubitemid 40978506)
31. MW Mayo AS Baldwin 2000 The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance Biochim Biophys Acta 1470 M55 M62 10722927 1:CAS:528:DC%2BD3cXhvFOhsbw%3D